Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
Novo Nordisk raised its 2026 outlook after reporting that Wegovy pill sales surged and outperformed expectations, with the medication reaching over 5 million prescriptions. The company cited improved demand for obesity and diabetes drugs, particularly outside the United States, as key drivers of the guidance increase.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Novo Nordisk raised its 2026 guidance after noting an improved outlook for its key obesity and diabetes drugs, particularly in markets outside the U.S.
- ✓ Wegovy pill sales surged 53% in Q3 2026 to approximately $811 million, beating analyst estimates by 17% as Medicare's new GLP-1 Bridge pilot program capped monthly costs at $50 for eligible seniors.
- ✓ The Wegovy pill has topped 5 million prescriptions.
- ✓ Novo Nordisk CEO said the Wegovy pill exceeded our expectations.
What changed
Novo Nordisk lifted its 2026 guidance following Q3 2026 results showing Wegovy pill sales of approximately $811 million, a 53% increase from the prior quarter.
Live updates
-
Novo Nordisk Lifts Guidance as Wegovy Pill Rollout Continues
Novo Nordisk raised its 2026 outlook after reporting that Wegovy pill sales surged and outperformed expectations, with the medication reaching over 5 million prescriptions. The company cited improved demand for obesity and diabetes drugs, particularly outside the United States, as key drivers of the guidance increase.
Why it matters
The Wegovy pill, a GLP-1 weight-loss medication, has intensified competition with Eli Lilly's Zepbound and Foundayo, especially as Medicare's GLP-1 Bridge pilot program caps monthly costs at $50 for eligible seniors. Novo Nordisk's CEO stated the Wegovy pill exceeded expectations, and the company is pursuing a volume-driven business model to sustain growth.
What is confirmed
- Novo Nordisk raised its 2026 guidance after noting an improved outlook for its key obesity and diabetes drugs, particularly in markets outside the U.S.
- Wegovy pill sales surged 53% in Q3 2026 to approximately $811 million, beating analyst estimates by 17% as Medicare's new GLP-1 Bridge pilot program capped monthly costs at $50 for eligible seniors.
- The Wegovy pill has topped 5 million prescriptions.
- Novo Nordisk CEO said the Wegovy pill exceeded our expectations.
Still unconfirmed
- One other earnings revelation boosted the stock beyond Wegovy performance.
- Euro area inflation data could impact future guidance.
What to watch next
- Q4 2026 earnings results and guidance updates
- Medicare GLP-1 Bridge program expansion beyond pilot
- Wegovy pill market share trends versus Eli Lilly's Zepbound and Foundayo
confidence 90%Sources used for this update (14)
- www.marketscreener.com — Global Stocks Fall on Higher Oil Prices, AI Pullback | MarketScreener
- Yahoo Finance — Novo Nordisk CEO: Wegovy pill 'exceeded our expectations'
- CNBC — Novo shares jump as Wegovy pill sales impress, drugmaker hikes outlook
- Barron's — Novo Nordisk Weight-Loss Pill Sales Soar. One Other Earnings Revelation Boosting the Stock.
- WSJ — Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
- The Economist — No pain, no gain at Novo
- www.techtimes.com — Wegovy Pill Outperforms Foundayo as Medicare Drives Novo's ...
- www.marketscreener.com — Hims & Hers to Offer Eli Lilly's Weight-Loss Drugs
- www.marketscreener.com — Eli Lilly, Him & Hers Team Up to Broaden Access to Obesity Drugs
- www.marketscreener.com — Novo Nordisk Lifts Outlook as Rollout of Wegovy Weight-Loss ...
- www.timeslive.co.za — Novo Nordisk lifts 2026 outlook as Wegovy pill surges - TimesLIVE
- ucapital.com — Novo Nordisk lifts its 2026 guidance on obesity drug demand
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community